McDermott Will & Emery advised Osivax on the deal. Osivax, a biopharmaceutical company developing broad-spectrum vaccines against highly mutated infectious viruses, signed an exclusive license option...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised eureKARE on the deal. eureKARE, investment company focused on financing and developing synthetic biology innovation across Europe, announced the creation...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Innate Pharma on the deal. Innate Pharma announced the expansion of its collaboration with Sanofi. Sanofi is licensing a natural killer...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery and Bredin Prat advised Five Arrows Principal Investments on the deal. Goodwin advised Latour Capital, Barings and Arcmont Asset Management. Latour Capital...
You must be a Standard 1 Year member to access this content.
McDermott has advised Acticor Biotech on the offering. Acticor Biotech, a clinical stage biopharmaceutical company dedicated to developing a drug for the treatment of cardiovascular emergencies,...
You must be a Standard 1 Year member to access this content.
